8 results about "Neo angiogenesis" patented technology

The application discloses a dual-specific antibody with functions of inflammation microenvironment regulation and simultaneous inhibition of choroidal neovascularization, and a preparation method and application thereof. The dual-specific antibody is a single-chain antibody, comprises an IL1R, an IL-1 receptor complex auxiliary subunit IL-1RAcP fragment, and extracellular domains D2 (VEGFR2D2) and D3 (VEGFR2D3) of a tyrosine kinase transmembrane receptor VEGFR2, can simultaneously bind to IL-1 and VEGF, has functions of regulating an inflammation microenvironment and inhibiting choroidal neovascularization, and can more accurately treat fundus-related diseases represented by age-related macular degeneration.

A macrophage-loaded drug-loaded nanoparticle, its preparation method, and its application belong to the field of drug-targeted carrier technology. To address the problem that the therapeutic efficacy of drugs such as lenvatinib for HCC after minimally invasive ablation is limited by their nonspecific accumulation and distribution in the body, the LEN-loaded MΦs prepared by the present invention are constructed by engulfing Escherichia coli membrane-coated LEN-loaded nanoparticles by natural M1-type MΦs. The E. coli membrane camouflage enhances the phagocytic efficiency of MΦs, prevents the leakage of LEN within the MΦs, and maintains the M1 type of LEN@MΦs within the immunosuppressive tumor microenvironment. The natural inflammatory gradient induced by ablation is used to guide LEN-loaded macrophages to target tumors, increasing the in vivo delivery efficiency of LEN in postoperative HCC by 10-fold. This method significantly inhibits tumor cell proliferation and angiogenesis, and this enhanced LEN delivery stimulates systemic immune responses and induces long-lasting immune memory.

The invention discloses an application of an FAP targeting drug and an anti-PD-1 antibody in combined treatment of colorectal cancer. The invention proves that the combined application of PT-100 and anti-PD-1 therapy shows good effects in the aspects of inhibiting colorectal cancer tumor growth, prolonging the survival time of mice, enhancing tumor cell apoptosis, inhibiting angiogenesis and remodeling tumor immune microenvironment by regulating immune cell subpopulation, and has acceptable tolerance. The invention provides a new treatment strategy and pharmaceutical composition for treatment of colorectal cancer, is expected to overcome the drug resistance of colorectal cancer immunotherapy, and also provides a theoretical basis for clinical transformation of combined application of an FAP strategy and immune checkpoint blocking.

The present invention discloses a compound Chinese medicine preparation, specifically a Chinese medicine powder for external use for treating diabetic foot ulcers. The powder is characterized in that it is prepared from the following raw materials in percentage by weight: 12-14% of whole scorpion, 12-14% of angelica, 12-14% of white ampel, 12-14% of red peony root, 7-9% of rhubarb, 7-9% of angelica dahurica, 7-9% of frankincense, 7-9% of myrrh, 7-9% of catechu, and 7-9% of dragon's blood. The Chinese medicine powder for external use can significantly treat diabetic foot ulcers by inhibiting inflammatory reactions and promoting angiogenesis.

The present invention relates to uses of an S1P receptor modulator such as 2-substituted derivatives of 2-amino-propane-1,3-diol or 2-1 amino-propanol, e.g. a compound comprising a group of formula (X) for the treatment or prevention of neoangiogenesis associated with a demyelinating disease.

The invention provides application of an NCOA3 polyQ structural domain in preparation of a medicine for relieving ocular vascular abnormal hyperplasia diseases, relates to the technical field of biomedicine, and aims to solve the problems that in the prior art, an ocular pathological angiogenesis mechanism is complex, and safe and effective targeted intervention means are lacked. The construction of a mouse corneal micropocket pathological angiogenesis model proves that Nco3polyQ structural domain deletion can significantly inhibit corneal neovascularization: compared with a WT mouse, the Nco3wt / Q mouse corneal tissue CD31 positive signal is reduced, the number of corneal neovascularization in the Nco3Q / Q mouse is minimum, and the CD31 positive area is minimum; meanwhile, qPCR (quantitative polymerase chain reaction) detection of corneal tissues shows that mRNA (messenger ribonucleic acid) expression of the vascular marker genes Pecam1 and Cdh5 is in a decreasing trend and is further decreased in an Nco3Q / Q mouse. On the basis, the intervention strategy aiming at the NCOA3 polyQ structural domain is used for preparing the medicine for relieving the abnormal hyperplasia diseases of the ocular blood vessels, and a new treatment strategy and a potential target are provided for related diseases of the ophthalmology department.

The invention discloses a poison drawing-out and tissue regeneration promoting gel and a preparation method thereof, and belongs to the field of pharmaceutics. The gel is prepared from poison drawing-out and tissue regeneration promoting powder, carbomer 940, glycerol, a pH regulator and water, and the stable gel is formed by regulating the pH to 6.0-7.4. The preparation method comprises the steps of gel matrix swelling, medicine dispersing, humectant adding, pH adjusting and homogenizing treatment. By improving the gel dosage form, the diffusion risk of mercury in traditional powder is remarkably reduced, and the drug stability and wound adhesion are improved. Experiments show that the gel can effectively inhibit bacterial biofilm formation and promote collagen synthesis and angiogenesis, and is especially suitable for repairing chronic ulcerative wounds such as burns and scalds.

The invention provides a preparation capable of inhibiting tumor angiogenesis, and belongs to the technical field of tumor angiogenesis inhibition. The preparation provided by the invention contains an inhibitor capable of obviously knocking out expression of VEGF, the inhibitor is siRNA, the siRNA is utilized to silence VEGF-mRNA, the silence efficiency is as high as 90%, the expression level of VEGF protein in HepG2 cells is effectively reduced, tumor angiogenesis can be better targeted, and tumor angiogenesis can be effectively inhibited. Therefore, the compound can be used for preparing a preparation with the effect of inhibiting tumor angiogenesis.